Pharma stock jumps 12% after its net profit increases by 91% in H1

Synopsis:
Curis Lifesciences’ shares rose 12% as H1FY26 revenue grew 76% YoY to  ₹ 27.90 Crores, while Net Profit surged 91% YoY to ₹ 4.21 Crores.

The shares of the Pharmaceutical stock company, specializing in manufacturing a diverse range of pharmaceutical products, including tablets, capsules, oral liquids, external preparations, and sterile ophthalmic ointments, jumped upto 12 percent after Profit Almost Doubled in  H1.

With a market capitalization of Rs. 100.93 Crores on Friday, the shares of Curis Lifesciences Limited jumped upto  11.9 percent, reaching a high of Rs. 129.00 compared to its previous close of Rs. 115.20.

What Happened

Curis Lifesciences Limited, engaged in manufacturing a diverse range of pharmaceutical products, including tablets, capsules, oral liquids, external preparations, and sterile ophthalmic ointments, has announced its H1 results as follows:

Its Revenue from operations rose by 76 percent YoY from Rs. 15.89 Crores in H1FY25 to Rs. 27.90 Crores in H1FY26, and it declined by 19 percent half-yearly from Rs. 34.36 Crores in H2FY25 to Rs. 27.90 Crores in H1FY26.

Its Net Profit YoY rose by 91 percent from Rs. 2.20 Crores in H1FY25 to Rs. 4.21 Crores in H1FY26, and it rose by 5.25 percent half-yearly from Rs. 4.00 Crores in H2FY25 to Rs. 4.21 Crores in H1FY26. The earnings per share (EPS) for the half-yearly period stood at Rs. 7.10, compared to Rs. 7.01 in the previous one.

Company Overview & Others

Curis Lifesciences Limited is an Indian pharmaceutical manufacturer based in Ahmedabad, Gujarat, specializing in diverse formulations, operating through contract/loan manufacturing for others (including big names like J B Chemicals) and direct exports, with a focus on quality via its WHO-GMP certified facility and aims to grow globally. Established in 2017 from a partnership, they serve over numerous clients and export to many countries, recently going public on the NSE SME platform. 

The company manufactures a range of pharmaceutical products, including tablets, capsules, external liquids (ointments, gels), oral liquids, and sterile ophthalmic ointments. Its business model is a blend of loan licensing, where it manufactures for other companies, contract manufacturing for various clients, and exports its own-brand products to markets in countries like Kenya, Yemen, and others. This mix allows for flexibility and diversification in its revenue streams.

The company takes pride in its ability to deliver exceptional solutions, ensuring long-term partnerships with companies such as Cadilla Pharmaceuticals, IPCA, Troikaa, and many others, by consistently exceeding client expectations and fostering innovation.

Written by Sridhar J 

Disclaimer

The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.

The post Pharma stock jumps 12% after its net profit increases by 91% in H1 appeared first on Trade Brains.